Survival of Patients With Idiopathic Pulmonary Arterial Hypertension After Listing for Transplantation: Impact of Iloprost and Bosentan Treatment
Authors:
- Michael DandelMDMichael Dandel
- Hans B. LehmkuhlHLHans B. Lehmkuhl
- Sead MulahasanovicSMSead Mulahasanovic
- Yuguo WengYWYuguo Weng
- Dagmar KemperDKDagmar Kemper
- Onnen GrauhanOGOnnen Grauhan
- Christoph KnosallaCKChristoph Knosalla
- Roland HetzerRHRoland Hetzer
- 1 September 2007
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 26 (9) , 898-906
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Preliminary Experience With Bosentan as Initial Therapy in Childhood Idiopathic Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2006
- Long-Term Outcome of Bosentan Treatment in Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with the Scleroderma Spectrum of DiseasesThe Journal of Heart and Lung Transplantation, 2005
- Prognosis of Pulmonary Arterial Hypertension*Chest, 2004
- Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertensionJACC, 2004
- End points and clinical trial designs in pulmonary arterial hypertensionJACC, 2004
- Prostanoids for Pulmonary Arterial HypertensionAmerican Journal of Respiratory Medicine, 2003
- Assessment of survival benefit after lung transplantation by patient diagnosisThe Journal of Heart and Lung Transplantation, 2002
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991